



(51) International Patent Classification:

A61P 11/06 (2006.01) A61K 31/505 (2006.01)
C07D 239/88 (2006.01)

(21) International Application Number:

PCT/EP2010/050243

(22) International Filing Date:

12 January 2010 (12.01.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/144,250 13 January 2009 (13.01.2009) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHEN, Weichun** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US). **KIM, Hong-Yong** [KR/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US). **LIANG, Jessica** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US). **MUTZ, Michael** [DE/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **PRASHAD, Mahavir** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US). **TOWLER, Christopher** [GB/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **WU, Ruochu** [CN/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080 (US).

(74) Agent: **VON SPRECHER, Georg**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))




Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

27 January 2011

(54) Title: QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS



(57) Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile having structural formula I(B) and to a method of preparing it. There is further a process or method for the manufacture of a pharmaceutically active quinazolinone compounds of the formula (I), wherein the symbols have the meanings given in the description, said process comprising reacting a compound of the formula (II), wherein R_4^* is $R_1^*-C(=O)-$ wherein R_1^* is independently selected from the group of meanings of R_1 as defined for a compound of the formula (I) so that R_1^* and R_1 are identical to or different from each other, or R_4^* is especially H, and R_1 and R_3 , R_5 and R_6 are as defined for a compound of the formula (I), or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula (III), wherein R_2 and m are as defined for a compound of the formula (I). Further reactions and related embodiments are also claimed and disclosed.